KRAS and pancreatic neoplasm: In phase 1 clinical study, it has been reported that the combination of dacomitinib and PD‐0325901 showed antitumor activity in KRAS‐mutation‐positive colorectal, pancreatic cancer, and NSCLC.[29] Similarly, the second screening demonstrated that dacomitinib inhibited the in vitro growth of Kras‐mutated EC organoids which displayed extensive resistance to these screened drugs.